In the study by Guess et al. [94] 800 mg Pecta-Sols powder-filled capsules were administered to each participant in the trial, with a total dosage of 18 capsules per day (14.4 g), to assess whether the prostate-specific antigen (PSA) doubling time (PSADT) of prostate cancer patients changed after taking MCP. Here, PROS1 is linked to prostate cancer.